Quest Diagnostics Incorporated (NYSE: DGX) announced that its board of directors has elected Timothy Wentworth as a new director, bringing the total number of board members to eleven.

Wentworth, 65, most recently served as chief executive officer of Walgreens Boots Alliance, where he helped restructure the company for its sale to Sycamore Partners in mid-2025. He previously held CEO positions at Evernorth Health Services, the health services organization of The Cigna Group, and Express Scripts, one of the largest pharmacy benefit managers in the United States.

At Express Scripts, Wentworth led the company following its 2012 acquisition of Medco Health Solutions, where he had served in senior roles including group president of employer accounts and president and CEO of Medco's Accredo Health specialty pharmacy business. The Medco transaction helped Express Scripts grow into a Fortune 25 company with more than $100 billion in revenues before Cigna acquired it in 2018.

Wentworth's experience also includes serving as chief operating officer at Mary Kay, Inc. and director roles in human resources at PepsiCo, Inc. He currently serves on the boards of directors of Walgreens Holding Company and Dfinitiv.

"As a former CEO of several large, publicly traded healthcare organizations, Tim brings incredible leadership experience to the Quest board," said Jim Davis, chairman, CEO and president of Quest Diagnostics.

Timothy M. Ring, lead independent director, stated that Wentworth "is an accomplished business leader who knows how to run highly complex, industry-leading healthcare companies to generate growth and value at scale."

Wentworth earned his bachelor's degree in industrial and labor relations from Cornell University and an associate in applied science degree in business administration from Monroe Community College.